Mary Wilson
Well-known member
Published: 06 June 2023
https://doi.org/10.1093/infdis/jiad210
Kevin M. Tuffy,1 Bahar Ahani,1 Anastasia A. Aksyuk,1 Miles Avila,1 Tyler Brady,1 Gustavo H. Kijak,1 Gavin Koh,2 Myron J. Levin,3 Tiffany L. Roe,1 Nicolette Schuko,1 Jesse Thissen,2Andrew Ustianowski,4 Tianhui Zhang,5 Elizabeth J. Kelly,1,1 and Katie Streicher1
Abstract
Background
We report spike protein-based lineage and AZD7442 (tixagevimab/cilgavimab) neutralizing activity of SARS-CoV-2 variants identified from breakthrough infections in the PROVENT pre-exposure prophylaxis trial (NCT04625725).
Methods
Variants identified from PROVENT participants with reverse-transcription polymerase chain reaction–positive symptomatic illness were phenotypically assessed to determine neutralization susceptibility of variant-specific pseudotyped virus-like particles.
Results
At completion of 6 months’ follow-up, no AZD7442-resistant variants were observed in breakthrough COVID-19 cases. SARS-CoV-2 neutralizing antibody titers were similar in breakthrough and non-breakthrough cases.
Conclusion
Symptomatic COVID-19 breakthrough cases in PROVENT were not due to resistance-associated substitutions in AZD7442 binding sites or lack of AZD7442 exposure.
https://watermark.silverchair.com/j...1wo6uX9e6DCkmZTHCxK84YJthEPobTzrAU7jrfWeFoPZM
https://doi.org/10.1093/infdis/jiad210
Kevin M. Tuffy,1 Bahar Ahani,1 Anastasia A. Aksyuk,1 Miles Avila,1 Tyler Brady,1 Gustavo H. Kijak,1 Gavin Koh,2 Myron J. Levin,3 Tiffany L. Roe,1 Nicolette Schuko,1 Jesse Thissen,2Andrew Ustianowski,4 Tianhui Zhang,5 Elizabeth J. Kelly,1,1 and Katie Streicher1
Abstract
Background
We report spike protein-based lineage and AZD7442 (tixagevimab/cilgavimab) neutralizing activity of SARS-CoV-2 variants identified from breakthrough infections in the PROVENT pre-exposure prophylaxis trial (NCT04625725).
Methods
Variants identified from PROVENT participants with reverse-transcription polymerase chain reaction–positive symptomatic illness were phenotypically assessed to determine neutralization susceptibility of variant-specific pseudotyped virus-like particles.
Results
At completion of 6 months’ follow-up, no AZD7442-resistant variants were observed in breakthrough COVID-19 cases. SARS-CoV-2 neutralizing antibody titers were similar in breakthrough and non-breakthrough cases.
Conclusion
Symptomatic COVID-19 breakthrough cases in PROVENT were not due to resistance-associated substitutions in AZD7442 binding sites or lack of AZD7442 exposure.
https://watermark.silverchair.com/j...1wo6uX9e6DCkmZTHCxK84YJthEPobTzrAU7jrfWeFoPZM